Skye Bioscience, Inc. Common Stock Market Cap ($5.40 Million)
Market Cap & Net Worth: Skye Bioscience, Inc. Common Stock (SKYE)
Skye Bioscience, Inc. Common Stock market cap. Skye Bioscience, Inc. Common Stock (NASDAQ:SKYE) has a market capitalization of $5.40 Million ($5.40 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28344 globally and #5837 in its home market, demonstrating a -22.29% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Skye Bioscience, Inc. Common Stock's stock price $1.22 by its total outstanding shares 4427676 (4.43 Million). Also see SKYE cash generation efficiency for how efficiently the company converts equity into cash flow.
Skye Bioscience, Inc. Common Stock Market Cap History (2015–2026)
Skye Bioscience, Inc. Common Stock market cap history from 2015 to 2026. Data shows change from $774.84 Million to $5.40 Million (-36.60% CAGR). Check latest Skye Bioscience, Inc. Common Stock stock price today for real-time trading data and today's change.
Index Memberships
Skye Bioscience, Inc. Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #809 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2601 of 3165 |
Weight: Skye Bioscience, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Skye Bioscience, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Skye Bioscience, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Skye Bioscience, Inc. Common Stock equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of SKYE by Market Capitalization
Companies near Skye Bioscience, Inc. Common Stock in the global market cap rankings as of November 4, 2026. Also see SKYE current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Skye Bioscience, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Skye Bioscience, Inc. Common Stock (2015–2026)
Market capitalization of Skye Bioscience, Inc. Common Stock from 2015 to today. Between 2015 and today, Skye Bioscience, Inc. Common Stock's market cap moved from $774.84 Million to $ 5.40 Million, with a yearly change of -36.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $5.40 Million | +62.73% |
| 2025 | $3.32 Million | -73.51% |
| 2024 | $12.53 Million | +4.04% |
| 2023 | $12.04 Million | -32.00% |
| 2022 | $17.71 Million | -69.23% |
| 2021 | $57.56 Million | +30.00% |
| 2020 | $44.28 Million | -69.47% |
| 2019 | $145.01 Million | -67.25% |
| 2018 | $442.77 Million | +163.16% |
| 2017 | $168.25 Million | -49.67% |
| 2016 | $334.29 Million | -56.86% |
| 2015 | $774.84 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Skye Bioscience, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.40 Million USD |
| MoneyControl | $5.40 Million USD |
| MarketWatch | $5.40 Million USD |
| marketcap.company | $5.40 Million USD |
| Reuters | $5.40 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Skye Bioscience, Inc. Common Stock
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1… Read more